articleTop 1% cited
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
European Journal of Cancer · 2011 · Vol. 47(14) · pp. 2117–2127
Masatoshi Kudo✉(Kindai University)Kazuho Imanaka(Osaka International Cancer Institute)Nobuyuki Chida(Sendai Medical Center)Kohei Nakachi(National Cancer Center Hospital East)Won Young Tak(Kyungpook National University Hospital)Tadatoshi Takayama(Nihon University)Jung‐Hwan Yoon(Seoul National University Hospital)Takeshi HoriHiromitsu Kumada(Toranomon Hospital)Norio Hayashi(Osaka University Hospital)Shuichi Kaneko(Kanazawa University Hospital)Hirohito Tsubouchi(Kagoshima University Hospital)Dong Jin Suh(Asan Medical Center)Junji Furuse(Kyorin University)Takuji Okusaka(Tokyo National Hospital)Katsuaki Tanaka(Yokohama City University Medical Center)Osamu Matsui(Kanazawa University)Michihiko Wada(Bayer (Japan))Iku Yamaguchi(Bayer (Japan))Toshio Ohya(Bayer (Japan))Gerold Meinhardt(Bayer (United States))Kiwamu Okita(Shimonoseki City Hospital)
Hepatocellular Carcinoma Treatment and PrognosisCancer Mechanisms and TherapyLiver physiology and pathologySorafenibMedicineHepatocellular carcinomaHazard ratioPlaceboInternal medicineClinical endpointCirrhosisAdverse effectGastroenterology
MeSH terms
SorafenibAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBenzenesulfonatesCombined Modality TherapyDouble-Blind MethodFemaleCarcinoma, HepatocellularHumansJapanLiver NeoplasmsMaleMiddle AgedNiacinamide
Funding
- Bayer HealthCare
- Onyx Pharmaceuticals
Citations
570
FWCI
22.19
field-weighted impact
References
36
Percentile
100%
vs. same field & year
Citations per year
Cited by
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Hepatology · 2023 · 1,480 citations
Hepatocellular carcinoma: clinical frontiers and perspectives
Gut · 2014 · 1,407 citations
Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma
CA A Cancer Journal for Clinicians · 2012 · 847 citations
Sorafenib in Advanced Hepatocellular Carcinoma
New England Journal of Medicine · 2008 · 12,835 citations
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2018 · 1,047 citations
Hepatocellular carcinoma review: Current treatment, and evidence-based medicine
World Journal of Gastroenterology · 2014 · 462 citations
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2014 · 2,255 citations
References
Sorafenib in Advanced Hepatocellular Carcinoma
New England Journal of Medicine · 2008 · 12,835 citations
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
Hepatology · 2003 · 3,004 citations
Hepatic artery embolization in 120 patients with unresectable hepatoma.
Radiology · 1983 · 989 citations
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
The Lancet Oncology · 2008 · 5,801 citations
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
Hepatology · 2002 · 2,609 citations
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Cancer Research · 2004 · 4,006 citations
Management of Hepatocellular Carcinoma: An Update Δσ
Hepatology · 2011 · 8,095 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.